 |
 |
Budipine provides additional benefit in patients with parkinson disease receiving a stable optimum dopaminergic drug regimen Budipine is an effective adjunct treatment for Parkinson's disease, according to this report. Budipine has a complex pharmacological profile with actions on dopaminergic, GABAergic, cholinergic, norepinephrinergic, and serotoninergic systems. 99 patients were randomized to receive placebo or budipine, titrated up to 60 mg/day for 16 weeks. Patients were on stable levodopa and bromocriptine treatment, with optional selegiline. Mean score on the Columbia University Rating Scale fell from approximately 35 to 20 in the treated group, versus 34 to 30 in the placebo group (p<0.001). Significant differences between the two groups were obtained for tremor, rigidity, and akinesia. Adverse events were significantly more common in the budipine-treated group, and included dizziness, dry mouth, loss of appetite, nervousness, and visual dysfunction. H Przuntek, S Bittkau, H Bliesath, U Büttner, G Fuchs, J Glass, H Haller, T Klockgether, P Kraus, L Lachenmayer, D Müller, T Müller, B Rathay, J Sgonina, V Steinijans, E Teshmar, G Ulm, D Volc Arch Neurol 2002;59:803-806 Copyright 2002 WE MOVE http://www.wemove.org janet paterson: an akinetic rigid subtype, albeit primarily perky, parky pd: 55/41/37 cd: 55/44/43 tel: 613 256 8340 email: [log in to unmask] smail: 375 Country Street, Almonte, Ontario, Canada, K0A 1A0 a new voice website: http://www.geocities.com/janet313/ ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn